



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/914,352	12/14/2001	Jens Mattsson	53631-65307	3692

466 7590 11/14/2003

YOUNG & THOMPSON
745 SOUTH 23RD STREET 2ND FLOOR
ARLINGTON, VA 22202

EXAMINER

NAVARRO, ALBERT MARK

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 11/14/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/914,352

Applicant(s)

MATTSSON, JENS

Examiner

Mark Navarro

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the corresponding address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-24 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). ____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____ 6) ☐ Other: ____

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1-3 and 18-19 in the response filed October 10, 2003 is acknowledged. The traversal is on the ground(s) that the claims were examined during the national stage and should be examined now. Applicants arguments are persuasive. Accordingly the restriction requirement is withdrawn and claims 1-24 are pending and under consideration.

Applicants attention is drawn to the preliminary amendment filed along with the application. Applicants attempt to amend claim 8 should have been to claim 9. To best correct this error, Applicants are requested to cancel these claims and then refile them as new claims 25-26.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

2. Claims 6, and 10-11 are directed to a sequence of nucleotides or antibodies which have the same characteristics as polynucleotides and antibodies found naturally and therefore does not constitute as patentable subject matter.

In the absence of the hand of man, naturally occurring products are considered non-statutory subject matter. Diamond v. Chakrabarty, 206 USPQ 193 (1980). Mere purity of

Art Unit: 1645

naturally occurring product does not necessarily impart patentability. Ex parte Siddiqui 156

USPQ 426 (1966). However when purity results in new utility, patentability is considered.

Merck Co. V. Chase Chemical Co. 273 F. Supp 68 (1967). See also American Wood v. Fiber

Disintegrating Co., 90 US 566 (1974); American Fruit Growers v. Brogdex Co. 283 US 1

(1931); Funk Brothers Seed Co. V. Kalo Inoculant Co. 33 US 127 (1948). Filing of evidence of

a new utility imparted by the increased purity of the claimed invention and amendment to the

claims to recite the essential purity of the claimed products is suggested to obviate this rejection.

For example, “An isolated nucleic acid/antibody...”

3. Claims 12-13, and 16-17 provides for the use of a protein, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 12-13 and 16-17 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 112

Art Unit: 1645

4. Claims 1, 5 and 14-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims are vague and indefinite in the recitation of "essentially/substantially identical/preserved." One of skill in the art would be unable to determine the metes and bounds of the claimed invention. For instance, what level of identity would qualify as "essentially identical" e.g., (90%, 70%, 50%, etc.)? Conversely at what point are the proteins no longer essentially identical? Without a clear definition as to the metes and bounds of the claimed invention, one of skill in the art would be unable to determine the metes and bounds of the phrase "essentially identical."

5. Regarding claims 2, 12, and 20 the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

6. Claim 6 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claim is vague and indefinite in the recitation of "stringent conditions." Possibilities for hybridization are determined by the stringency of the procedure. Stringency, determined by the physical and chemical conditions, establishes the degree of hybridization. Without providing the chemical and physical conditions under which the hybridization is to be performed as well as

that of the wash step, one of skill in the art would be unable to determine the metes and bounds of the claimed invention.

7. Regarding claim 9, the phrase "optionally" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

8. Claim 13 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claim is vague and indefinite in the recitation of the phrase "similar biological activities." One of skill in the art would be unable to determine the metes and bounds of the claimed invention. For instance what activity is being measured, antigenicity, immunogenicity, enzymatic activity, chemotactic activity, etc. Furthermore once the activity is determined what level of similar activity qualifies as "similar" (e.g. 95%, 75%, 50%, etc.)? Without a clear definition as to the metes and bounds of the term "similar" biological activity, one of skill in the art would be unable to determine the metes and bounds of the claimed invention.

9. Claims 14-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims are vague and indefinite in the recitation of the phrase “analogues that mimic” at least a part of the structure of the protein. One of skill in the art would be unable to determine the metes and bounds of the claimed invention. For instance what level of structure identity is required to be a “mimic?” Applicants claim language of “substantially preserved” does not shed any light on this ambiguity.

10. Claim s 1-24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are directed to an isolated mite protein comprising at least about 83 amino acids of the sequence disclosed in SEQ ID NO: 2, said 83 amino acids being essentially identical to the amino acid sequence disclosed in SEQ ID NO: 3.

The specification and claims do not indicate what distinguishing attributes are shared by the members of the genus. Thus, the scope of the claims includes numerous structural variants, and the genus is highly variant because a significant number of structural differences between genus members is permitted. Since the disclosure fails to describe the common attributes or characteristics that identify members of the genus, and because the genus is highly variant, SEQ ID NO: 2 alone is insufficient to describe the genus. One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus. Thus, applicant was not in possession of the claimed genus. Furthermore, since SEQ ID

NO: 2 is a fragment of a full length protein, the written description is only commensurate in scope with this fragment, thus the claims are only adequately described for “consisting of” the identified fragment, since additional amino acids on the N or C terminus will have a profound effect on the activity of the protein.

Adequate written description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it. The protein itself is required. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016.

Applicants are directed to the Revised Interim Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, 1 “Written Description” Requirement, Federal Register, Vol. 64, No. 244, pages 71427-71440, Tuesday December 21, 1999.

11. Claims 16-21 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an immunogenic composition consisting of SEQ ID NO: 2 does not reasonably provide enablement for vaccines comprising SEQ ID NO: 2. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Facts that should be considered in determining whether a specification is enabling, or if it would require an undue amount of experimentation to practice the invention include: (1) the quantity of experimentation necessary to practice the invention, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the

Art Unit: 1645

invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims. See In re Wands, 858 F.2d 731,737, 8 USPQ2d 1400, 1403 (Fed. Cir. 1988). The Federal Circuit has noted, however, that only those factors that are relevant based on the facts need to be addressed. See Enzo Biochem. Inc. v. Calgene, Inc. 188 F.3d 1362, 1371, 52 USPQ2d 1129, 1135 (Fed. Cir 1999).

The specification provides insufficient guidance of how to use the claimed polypeptides as a pharmaceutical for the prevention of disease. It is well recognized in the art that it is unclear whether a single protein derived from a pathogen will elicit protective immunity. Ellis, R.W. (see Chapter 29 of "VACCINES" [Plotkin, S.A et al.,(ed.), published by W.B. Saunders Company (Philadelphia) in 1988, especially page 571, 2nd full paragraph] exemplifies this problem in the recitation that "The key to the problem (of vaccine development) is the identification of that protein component of a virus or microbial pathogen that itself can elicit the production of protective antibodies ...and thus protect the host against attack by the pathogen."

In view of the lack of guidance, lack of examples, and lack of predictability associated with regard to producing and using the proteins encompassed in the scope of the claims one skilled in the art would be forced into undue experimentation in order to practice broadly the claimed invention.

12. Claim 8 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for recombinant host cells, does not reasonably provide enablement for all recombinant cells. The specification does not enable any

person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Applicant's specification demonstrates the transformation of heterologous DNA into *E. coli*. However, this does not provide enablement for all transgenic host cells. Transgenic host cells can include human cell lines. Applicant's have provided no guidance or working examples of any transformed cell line other than a prokaryotic *E. coli* strain.

Vas-Cath Inc. V. Mahurkar, 19 USPQ2d 111, clearly states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117). The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See page 1116). Adequate written description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, 18 USPQ2d 1016.

Thus, Applicant's have not provided sufficient guidance to enable one skilled in the art to make and use any transgenic cell in a manner reasonably correlated with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without such guidance, the changes which can be made is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See Ex parte Forman, 230 USPQ 546 (Bd. Pat. App. & Int. 1986).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

13. Claim 6 is rejected under 35 U.S.C. 102(b) as being anticipated by Birkett.

The claims are drawn to a nucleic acid which hybridizes specifically under stringent conditions to a nucleic acid according to claim 4.

Birkett et al (U.S. Patent Number 5,302,527) disclose of random priming with a mixed hexamer oligonucleotide kit (Multiprime Kit, Amersham). (See column 15 lines 25-30).

In view that Birkett disclose of oligomers containing every possible combination of nucleotides for 6 mers, and that these sequences will inherently hybridize to DNA encoding the protein of SEQ ID NO: 2 under the recited conditions, the disclosure of Birkett et al is deemed to anticipate the claimed invention.

14. Claims 14-15 are rejected under 35 U.S.C. 102(e) as being anticipated by Hsu.

The claims are directed to a method for screening protein or peptide analogues that mimic at least a part of the structure of the protein according to claim 1, which comprises the steps of producing a multiplicity of analogue structures and selecting an analogue structure, wherein the three dimensional configuration and spatial arrangement of one or more biologically active regions remain substantially preserved.

Hsu (US Patent Number 6,171,800) disclose of evaluating compounds for the ability to inhibit or promote an interaction with a CAIP like family polypeptide. (See column 9).

In view that Hsu disclose of screening analogues for the ability to mimic the activity of a CAIP like polypeptide, the disclosure of Hsu is deemed to anticipate the claimed invention. It is noted that the claims further recite a "three-dimensional configuration and spatial arrangement... substantially preserved." Given that the degree of preservation is not set forth, the CAIP like polypeptides are deemed to be "substantially preserved."

Art Unit: 1645

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark Navarro whose telephone number is (703) 306-3225. The examiner can normally be reached on 5/4/9.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (703) 308-3909. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



Mark Navarro
Primary Examiner
November 3, 2003